RedChip Companies
|
Weekly Newsletter
|
|
|
BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials
|
BioVie (Nasdaq: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced positive results from two Phase 2 trials assessing NE3107’s potential in Parkinson’s Disease and Alzheimer’s Disease.
“NE3107 shows promise, and if the current findings are confirmed, it may represent one of the most significant advances in Parkinson’s treatment in decades,” commented Joseph Palumbo, BioVie’s Chief Medical Officer.
Dr. Sheldon Jordan, Principle Investigator, added, “Through our work, we are seeking to deepen our understanding of brain degeneration and ultimately identify promising treatments that have the potential to counteract the degenerative process. Results from this trial provide encouraging signals that NE3107 may offer significant potential to reduce neuroinflammation and potentially improve metabolic parameters such as glutathione in the brain, and warrant further study in this patient population.”
For more information, visit www.bioviepharma.com
|
|
EF Hutton - DGLY: Proposed TicketSmarter Separation Expected to Unlock Shareholder Value
|
|
Sidus Space Selects Exolaunch for LizzieSatTM Deployment During LizzieSat Rideshare Missions with SpaceX
Sidus Space (Nasdaq: SIDU), a Space-as-a-Service company focused on mission critical hardware manufacturing combined with commercial satellite design, manufacture, launch, and data collection, recently signed an agreement with Exolaunch to use their CarboNIX separation system to deploy LizzieSat(TM) satellites during the LizzieSat rideshare missions with SpaceX in 2023 and 2024. This agreement includes comprehensive technical support that ensures safe, reliable LizzieSat microsatellite deployment. John Curry, Sidus Chief Mission Operations Officer, says “Sidus’s highest priority is getting LizzieSat and our customers into space safely and reliably. This Exolaunch multi-mission agreement to deploy LizzieSats from the launch vehicle provides Sidus customers high confidence their hosted payloads will arrive safely in orbit.”
|
KWESST Micro Systems Inc. Announces Closing of Public Offerings for USD $14.1 Million in Aggregate Gross
KWESST Micro Systems (Nasdaq: KWE) raised $14.1 million in a public offering that coincided with its uplist to Nasdaq. KWESST develops and commercializes breakthrough next-generation tactical systems that meet the requirements of security forces and personal defense for overmatch capability against adversaries. The company's current portfolio of unique proprietary offerings include its unique non-lethal PARA OPS(TM) system with application across all segments of the non-lethal market, including law enforcement and personal defense. KWESST is also engaged in the digitization of tactical forces for shared situational awareness and targeting with its signature TASCS (Tactical and Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users' smart devices and weapons. Other KWESST products include counter-measures against threats such as electronic detection, lasers and drones.
|
|
|
QYOU Media Reflects on a Year of Rapid Growth
QYOU Media (OTCQB QYOUF), a company operating in India and the United States producing and distributing content created by social media stars and digital content creators, has broken new ground in 2022. For the nine months ended September 30, 2022, QYOU Media’s revenue grew 156% with record quarterly revenues reported for two consecutive quarters, achieving $6.8m in Q2 and $7.2m in Q3. QYOU Media now reaches over 125 million viewers weekly on Q branded content channels and is aiming to drive that number to 200 million by mid-2023.
|
Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3
Nutriband (Nasdaq: NTRB), a developer of transdermal pharmaceutical products, generated record quarterly revenue in Q3, up 118% over the prior year period. "Once again, we have had a record quarter for our revenue generating subsidiaries. Building on these revenue streams remains an important focus for us as we continue to develop AVERSA Fentanyl.," commented Gareth Sheridan, CEO of Nutriband. "According to the assessment by Health Advances, AVERSA Fentanyl could reach peak annual sales of between $80 to $200 million. If the entire transdermal fentanyl market moves toward abuse deterrent patches, similar to what occurred in the extended-release oral opioid market, the potential could be significantly greater.”
|
|
|
Upcoming Events |
|
|
|
NYSE American: CANF - Can-Fite BioPharma Ltd. |
11:00am Eastern |
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Psoriasis, and liver diseases including advanced liver cancer and NASH. |
|
|
|
|
NASDAQ: NTRB - Nutriband |
4:15pm Eastern |
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies, benefitting patients, physicians, and payers. |
|
|
|
|
NASDAQ: SYTA - Siyata Mobile |
4:15pm Eastern |
Siyata Mobile (Siyata or the Company) is a leading developer and distributor of technologically advanced rugged smartphones, in-vehicle mounted IoT cellular communications devices, and cellular signal boosters for global first responders and enterprise customers based on Push-to-Talk Over Cellular (PoC) technology. |
|
|
|
|
NASDAQ: ASPI - ASP Isotopes |
11:00am Eastern |
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. |
|
|
|
|
NASDAQ: UNCY - Unicycive Therapeutics Inc. |
4:15pm Eastern |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. |
|
|
|
|
NASDAQ: DGLY- Digital Ally Inc. |
4:15pm Eastern |
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. |
|
|
Archive Events |
|
|
|
NASDAQ: RVSN - Rail Vision |
Meeting Duration 33 minutes |
Rail Vision is the leading provider of obstacle detection and classification systems in the railway industry. With the Company’s unique cognitive sensor fusion technology, based on advanced electrooptic sensors, artificial intelligence and deep learning, Rail Vision systems detect objects on and along the tracks from a distance of up to two kilometers – in real time – as well as in all weather and light conditions. |
|
|
|
|
NYSE American - DSS |
Meeting Duration 30 minutes |
DSS Inc. is a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, securitized digital assets, securities trading and fund management, and banking, lending, and finance. Its business model is based on a distribution sharing system in which shareholders receive shares in its subsidiaries as DSS strategically unlocks value through IPO spin offs. |
|
|
|
|
NASDAQ: GENE - Genetic Technologies Limited |
Meeting Duration 29 minutes |
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. |
|
|
|
|
NASDAQ: IINN - Inspira Technologies |
Meeting Duration 31 minutes |
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. |
|
|
|
|
OTCQB: ILAL - International Land Alliance |
Meeting Duration 46 minutes |
International Land Alliance (ILAL) is a developer of residential communities in Northern Baja California with projects are targeted at buyers and investors of primary, vacation, and/or retirement homes. |
|
|
|
|
NASDAQ: DPRO - Draganfly |
Meeting Duration 49 minutes |
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. |
|
|
Lesson of the Week
Microcap pros make millions by buying before the crowd.
|
|
|
RedChip TV |
MidSouth Week in Review
The 30-year Treasury bond yield declined to 3.53%.
|
|
|
You are receiving this email because your email is subscribed to our mailing list.
Click here to unsubscribe your email address from this list.
Copyright © 2022. All rights reserved.
|
© 2022 RedChip , All rights reserved
|
|
|
|
|
|